REG-4basebio Plc: Director Dealing

4BasebioAnnouncement

Mon 07:02

16 February 2026

4basebio PLC

("4basebio" or the "Company")

Director Dealing

Cambridge, UK, 16 February 2026                                              
                                                  – 4basebio PLC (AIM:
4BB), an innovation driven biotechnology company enabling and accelerating
development of advanced therapy medicinal products (ATMPs) through its high
performant GMP-grade synthetic DNA products, announces that on 13 February
2026 it was informed that Dr. Amy Walker, Chief Executive Officer of the
Company made the following purchase in ordinary shares in the capital of the
Company through the market.

Further details are set out in the Notification of Dealing Form below.

 Director / PCA  Number of Ordinary Shares Acquired  Purchase Price (Aggregated) (p)  Shareholding Following Acquisition  Shareholding Following Acquisition as a Percentage of Issued Share Capital  
 Dr. Amy Walker  2,650                               586.08                           46,666                              0.30%                                                                       

The 2,650 shares purchased represent approximately 0.02 per cent. of the
Company's issued share capital.

The issued share capital of the Company comprises 15,538,518 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC                                                                                                                                                                                                                                                                                                                                                                      +44 (0)12 2396 7943  
 Dr Amy Walker, CEO                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                        
 Cairn Financial Advisers LLP (Nominated Adviser                                                                                                                  )                                                                                                                                                                                                                +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson / Ed Downes                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                        
 Cavendish Capital Markets Limited (Joint Broker)                                                                                                                                                                                                                                                                                                                                  +44 (0)20 7220 0500  
 Geoff Nash / Nigel Birks                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                        
 RBC Capital Markets (Joint Broker)                                                                                                                                                                                                                                                                                                                                                +44 (0)20 7653 4000  
 Kathryn Deegan / Matthew Coakes                                                                                                                                 ICR Healthcare (Media and Investor Relations)                                                                                                                                Mary-Jane Elliott / Jessica Hodgson  +44 (0)203 707 5700  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 1   Details of the persons discharging managerial responsibilities / person closely associated                                                                                                                                                                                                                                                                                                            
 a)  Name                                                                                                                                                                                                                                                                                               Dr. Amy Walker                                                                                     
 2   Reason for the notification                                                                                                                                                                                                                                                                                                                                                                           
 a)  Position/Status                                                                                                                                                                                                                                                                                    Chief Executive Officer                                                                            
 b)  Initial notification/ Amendment                                                                                                                                                                                                                                                                    Initial notification                                                                               
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                                                                                                                                                                                                                         
 a)  Name                                                                                                                                                                                                                                                                                               4basebio plc                                                                                       
 b)  LEI                                                                                                                                                                                                                                                                                                213800E2DX9EAIUNCB30                                                                               
 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted                                                                                                                                                                                                     
 a)  Description of the financial                                                                       instrument, type of                                                                       instrument                                                                       Identification code  Ordinary Shares                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                             ISIN: GB00BMCLYF79                                            
 b)  Nature of the transaction                                                                                                                                                                                                                                                                          Acquisition of ordinary shares                                                                     
 c)  Price(s) and volume(s)                                                                                                                                                                                                                                                                                                                                                                                
     Price(s)                                                                                                                                                                                                                                                                                           Volume(s)                                                                                          
     586.08p                                                                                                                                                                                                                                                                                            2,650                                                                                              
 d)  Aggregated information                                                                       -      Aggregated volume                                                                       -      Aggregated Price                                                                                2,650                                                                       586.08p                
 e)  Date of transaction                                                                                                                                                                                                                                                                                13 February 2026                                                                                   
 f)  Place of transaction                                                                                                                                                                                                                                                                               London Stock Exchange                                                                              



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved